Oncologic outcome of robot-assisted laparoscopic prostatectomy in the high-risk setting

Journal of Endourology

Volumn 24, Issue 12, 2010, Pages 1963-1966

  Engel, Jason D ^a   Kao, William W ^a   Williams, Stephen B ^b   Hong, Y Mark ^a  

^a GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATECTOMY; RECURRENT DISEASE; ROBOT ASSISTED LAPAROSCOPIC PROSTATECTOMY; ROBOTICS; TREATMENT FAILURE;

AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; PROSTATECTOMY; RISK FACTORS; ROBOTICS; TREATMENT OUTCOME;

EID: 78650288492     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2010.0305     Document Type: Article

References (23)

1. Denberg TD, Glode LM, Steiner JF, et al. Trends and pre-dictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int 2006;98:335-340.
2. Meng MV, Elkin EP, Latini DM, et al. Treatment of patients with high risk localized prostate cancer: Results from can-cer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005;173:1557-1561.
3. Yossepowitch O, Eastham JA. Radical prostatectomy for high-risk prostate cancer. World J Urol 2008;26:219-224.
4. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortal-ity in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008;53:950-959.
5. Yossepowitch O, Eggener SE, Bianco FJ Jr, et al. Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. J Urol 2007;178:493-499.
6. Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95:751-756.
7. Berglund RK, Jones JS, Ulchaker JC, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis. Urology 2006;67:1253-1256.
8. Gontero P, Marchioro G, Pisani R, et al. Is radical prosta-tectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 2007;51:922-930.
9. Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007;69:1170-1175.
10. Intuitive Surgical, Inc, 2008 Annual Report. Available at: www.intuitivesurgical.com. Accessed June 22, 2009.
11. Blute ML. No proof of inferiority: Open radical retropubic prostatectomy remains state-of-the-art surgical technique for localized prostate cancer. J Urol 2009;181:2421-2423.
12. Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55:1251-1265.
13. Gerber GS, Thisted RA, Chodak GW, et al. Results of radi-cal prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol1997;32: 385-390.
14. Boorjian SA, Blute ML. Surgical management of high risk prostate cancer: The Mayo Clinic experience. Urol Oncol 2008;26:530-532.
15. Kaul S, Diaz M, Krane LS, et al. Oncological outcomes fol-lowing robotic radical prostatectomy (RARP) in patients with D'Amico high risk prostate cancer: Predictors of adverse outcomes on multivariate analysis. J Urol 2009;181(suppl1). Abstract 1012.
16. Choueiri TK, Chen MH, D'Amico AV, et al. Impact of postoperative prostate specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010;116:1187-1192.
17. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatec-tomy. JAMA 2008;299:2760-2769.
18. Kane CJ, Presti JC Jr, Amling CL, et al. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007;177:113-117.
19. Badani KK, Kaul S, Menon M. Evolution of robotic radical prostatectomy: Assessment after 2766 procedures. Cancer 2007;110:1951-1958.
20. Van Poppel H, Vekemans K, Da Pozzo L, et al. Radical prostatectomy for locally advanced prostate cancer: Results of a feasibility study (EORTC 30001). Eur J Cancer 2006;42: 1062-1067.
21. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-S27.
22. D'Amico AV, Whittington R, Malkowicz SB, et al. Bio-chemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clini-cally localized prostate cancer. JAMA 1998;280:969-974. (Pubitemid 28445094)
23. Nguyen CT, Reuther AM, Stephenson AJ, et al. The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol 2009; 181:75-80.